Fig. 4Figure 4
Effects of CD38 siRNA in focal cerebral ischemia a, Male C57Bl6 mice were subjected to transient 60 min focal
ischemia and control siRNA or CD38 siRNA was injected into lateral ventricles at
5 days post-stroke. Immunostaining showed that CD38 siRNA decreased HMGB1
astrocytes in peri-infarct cortex. b, Nissl staining showed no
difference in infarct size (n=8 or 10). c, Immunostaining
demonstrated that astrocytic CD38 was diminished by CD38 siRNA. d,
Astrocytic CD38 suppression with siRNA reduced GFAP-positive mitochondria in CSF
at 7 days (n=6). e, Neuronal mitochondria were decreased by
CD38 siRNA (n= 8 or 5). f, CD38 siRNA attenuated
peri-infarct GAP43 immunostaining. g, Western blot confirmed a
reduction of peri-infarct GAP43 protein within CD38 siRNA-treated brains
(n=5). h, i, Suppression of CD38 signaling worsened
neurological outcomes in neuroscore ( h ) and grid walking test
( i ) (n=7 or 9).* P <0.05 vs
day 3 control siRNA, # P <0.05 vs day 7
CD38 siRNA. j, CD